The university spin-off UDIBI continues its unstoppable ascension: after being recently recognized by Cofepris, Mexico’s sanitary agency, as an authorized laboratory to assess biotech treatments entering the Mexican market, UDIBI has no started to develop its own, innovative compounds. Sonia Mayra Peréz Tapia, executive director of UDIBI, highlights the ambitious development path followed by an organization which steadily becomes a true, research-driven biotech company, while its remarkable scientific capacity and its cost-efficient service offering also draws the interest of an increasing number of customers, in Mexico and abroad.
UDIBI truly showcases how, with the right approach and the right people, it is possible to turn a Mexican university spin-off into a success-story holding promising developments and opportunities. As a matter of fact, in April, 2015, UDIBI was officially recognized by Cofepris as an authorized laboratory for market pre-approval. What does this recognition mean for UDIBI?
Being recognized as a laboratory that holds the technical expertise to conduct pre-approval market authorization on behalf of Cofepris, Mexico’s regulatory agency, indisputably stands a formidable achievement.
